Contents
Market Overview
Slovenia is emerging as one of Europe’s most progressive medical cannabis markets, following a comprehensive legislative overhaul in mid-2025. The country first legalised medical cannabis in March 2017, when cannabis was reclassified from a Schedule 1 narcotic (no medical value) to a Schedule 2 substance with recognised therapeutic potential.
However, under the 2017 law, access remained largely theoretical. Although medical cannabis flowers and extracts could be prescribed magistrally via special exemptions from the Public Agency of the Republic of Slovenia for Medicinal Products and Medical Devices (JAZMP), prescriptions were rarely issued, and patient access was virtually non-existent.
That changed dramatically with the passage of the Medical Cannabis Measure on 15 July 2025. The new legislation introduces an open licensing framework for commercial operations and grants physicians broad discretion to prescribe medical cannabis, positioning Slovenia among Europe’s most liberal and commercially accessible markets.
Regulatory Framework
The Medical Cannabis Measure (2025) replaces the restrictive 2017 framework and establishes a comprehensive regulatory system for cultivation, production, distribution, and patient access. It also introduces clear roles for the Slovenian Agency for Medicinal Products and Medical Devices (JAZMP), which now oversees the licensing and compliance of all operators within the medical cannabis supply chain.
Key regulatory features include:
- Open Licensing Model: Any company meeting JAZMP’s technical and quality standards can apply for a licence to cultivate, manufacture, distribute, or export medical cannabis.
- Product Scope: Includes both flowers and extract-based formulations (oils, capsules, tinctures).
- Quality Standards: All operators must comply with EU-GMP and GACP requirements for medical-grade products.
- Prescription Model: Cannabis is recognised as a controlled prescription medicine, subject to monthly dispensing limits.
The new framework aligns Slovenia with leading European jurisdictions such as Germany and the Czech Republic, while offering a more streamlined commercial entry process and broader physician autonomy.
Patient Access
Who Can Prescribe?
Under the 2025 Medical Cannabis Measure, any licensed physician in Slovenia is authorised to prescribe medical cannabis for any condition they deem clinically appropriate.
Prescription Parameters:
- Prescriptions are limited to a one-month supply per patient to ensure responsible use and prevent diversion.
- Follow-up appointments are required for renewal, with medical documentation verifying therapeutic need.
- Dispensing occurs through pharmacies authorised by JAZMP, ensuring product quality and traceability.
Treatment Indications:
There are no predefined lists of eligible conditions. However, initial guidance from the Ministry of Health suggests priority use in:
- Chronic and neuropathic pain
- Spasticity and multiple sclerosis
- Chemotherapy-induced nausea and vomiting
- Epilepsy and seizure disorders
- Appetite loss and cachexia
- Anxiety and sleep-related disorders
This open-prescription framework distinguishes Slovenia from most European markets, where medical cannabis is typically limited to specific pathologies.
Industry and Licensing Landscape
The introduction of the open licensing system has created significant commercial interest. Slovenia’s climate, agricultural base, and EU membership position it as an attractive location for investment in cultivation, processing, and export operations.
As of Q3 2025, JAZMP has begun accepting applications for:
- Cultivation and processing licences (for medical cannabis and extracts)
- Wholesale distribution and export authorisations
- Pharmacy compounding and dispensing approvals
Early indications suggest several domestic pharmaceutical and agricultural companies are partnering with international producers to establish EU-GMP-certified facilities targeting both domestic supply and export to Germany, Poland, and Italy.
Outlook
Slovenia’s 2025 Medical Cannabis Measure marks a decisive shift from symbolic legality to practical accessibility. By combining broad prescribing rights, open licensing, and EU-aligned compliance standards, the country is poised to become a regional hub for medical cannabis production and innovation.
In the short term, patient numbers are expected to rise rapidly as physicians gain familiarity with prescribing procedures and pharmacies establish stock availability. In the medium term, Slovenia’s policy clarity and export potential could position it as a Central European leader in both medical cannabis access and commercial production.
